BioAge Labs (BIOA)
15.74
+0.23 (1.48%)
Upcoming Events
Latest Headlines
Number of shares and votes in BioArctic AB (publ) as of May 29, 2026
May 30, 2026 4:32 AM - PR NewsWire
Bulletin from the Annual General Meeting in BioArctic AB (publ)
May 28, 2026 1:35 PM - PR NewsWire
Roth/MKM Starts BioAge Labs Inc (BIOA) at Buy
May 27, 2026 1:05 AM - StreetInsider
BioArctic's partner Eisai presents sales simulation of potential future sales of Leqembi® at its Investor Relations Day
May 25, 2026 3:34 AM - PR NewsWire
BioAge Labs to Present at Upcoming Investor Conferences
May 22, 2026 9:00 AM - Globe NewsWire
Form SCHEDULE 13G/A BioAge Labs, Inc. Filed by: Khosla Ventures VI, L.P.
May 15, 2026 4:21 PM - SEC Filing
Form SCHEDULE 13G/A BioAge Labs, Inc. Filed by: Cormorant Asset Management, LP
May 15, 2026 1:19 PM - SEC Filing
Eisai projects Leqembi® revenue to total JPY 143.5 billion for fiscal year 2026 (April 2026 - March 2027)
May 15, 2026 2:56 AM - PR NewsWire
BTIG Starts BioAge Labs Inc (BIOA) at Buy
May 13, 2026 5:34 AM - StreetInsider
Invitation to presentation of BioArctic's first quarter report for January - March 2026 on May 20 at 9:30 a.m. CET
May 13, 2026 2:59 AM - PR NewsWire
BioAmber (BIOA) Reports Q1 Loss of $0.52
May 8, 2026 9:30 AM - StreetInsider
Form 8-K BioAge Labs, Inc. For: May 08
May 8, 2026 9:10 AM - SEC Filing
Form 10-Q BioAge Labs, Inc. For: Mar 31
May 8, 2026 9:06 AM - SEC Filing
BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates
May 8, 2026 9:00 AM - Globe NewsWire
FDA extends Leqembi Iqlik review period to August 24
May 8, 2026 2:48 AM - StreetInsider
FDA extends Leqembi Iqlik review period to August 24
May 8, 2026 2:48 AM - StreetInsider
Leqembi® Iqlik™ PDUFA date updated to August 24 in the U.S.
May 8, 2026 2:48 AM - PR NewsWire
BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026
May 4, 2026 4:30 PM - Globe NewsWire
Form SCHEDULE 13G BioAge Labs, Inc. Filed by: BlackRock, Inc.
April 27, 2026 4:13 PM - SEC Filing
Form 4 BioAge Labs, Inc. For: Apr 23 Filed by: GOLDSTEIN DOV A MD
April 24, 2026 4:19 PM - SEC Filing
Form ARS BioAge Labs, Inc. For: Dec 31
April 21, 2026 4:27 PM - SEC Filing
Form DEFA14A BioAge Labs, Inc.
April 21, 2026 4:07 PM - SEC Filing
Form DEF 14A BioAge Labs, Inc. For: Jun 10
April 21, 2026 4:06 PM - SEC Filing
BioArctic publishes the Annual Report and Sustainability Report for 2025
April 21, 2026 3:18 PM - PR NewsWire
Jefferies on BioAge Labs Inc (BIOA): lower dose data reinforces potential BIC, 'layers of momentum build'
April 21, 2026 2:46 PM - StreetInsider
BioAge reports phase 1 results for NLRP3 inhibitor BGE-102
April 21, 2026 7:01 AM - StreetInsider
BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP
April 21, 2026 7:00 AM - Globe NewsWire
BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference
April 13, 2026 4:30 PM - Globe NewsWire
Form 4 BioAge Labs, Inc. For: Apr 01 Filed by: RUBIN PAUL D
April 3, 2026 4:07 PM - SEC Filing
Form 144 BioAge Labs, Inc. Filed by: RUBIN PAUL D
April 1, 2026 10:54 AM - SEC Filing
Needham Starts BioAge Labs Inc (BIOA) at Buy
March 27, 2026 6:14 AM - StreetInsider
The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB
March 27, 2026 5:13 AM - PR NewsWire
BioAge Labs (BIOA) files mixed shelf
March 24, 2026 4:27 PM - StreetInsider
Form S-3ASR BioAge Labs, Inc.
March 24, 2026 4:22 PM - SEC Filing
Form S-8 BioAge Labs, Inc.
March 24, 2026 4:08 PM - SEC Filing
Jefferies on BioAge Labs Inc (BIOA): 'stock setup from here is very attractive'
March 24, 2026 3:38 PM - StreetInsider
Oppenheimer stays Outperform on BioAge Labs Inc (BIOA) following Q4 earnings update
March 24, 2026 3:04 PM - StreetInsider
Form 10-K BioAge Labs, Inc. For: Dec 31
March 24, 2026 9:16 AM - SEC Filing
Form 8-K BioAge Labs, Inc. For: Mar 24
March 24, 2026 9:11 AM - SEC Filing
BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025
March 24, 2026 9:00 AM - Globe NewsWire
New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congress
March 23, 2026 3:50 AM - PR NewsWire
Full Article List
